

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)



(10) International Publication Number
WO 2022/197949 A2

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2022/020787
- (22) **International Filing Date:**
17 March 2022 (17.03.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/162,352 17 March 2021 (17.03.2021) US
63/172,922 09 April 2021 (09.04.2021) US
63/243,947 14 September 2021 (14.09.2021) US
63/255,540 14 October 2021 (14.10.2021) US
- (71) **Applicant: MYELOID THERAPEUTICS, INC.**
[US/US]; 300 Technology Square, Suite 203, Cambridge, MA 02139 (US).
- (72) **Inventors: GETTS, Daniel;** c/o Myeloid Therapeutics, Inc., 300 Technology Square, Suite 203, Cambridge, MA 02139 (US). **WANG, Yuxiao;** c/o Myeloid Therapeutics, Inc., 300 Technology Square, Suite 203, Cambridge, MA 02139 (US).
- (74) **Agent: GHOSH, Sanjukta;** Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) **Title:** ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF




FIG. 1C

(57) **Abstract:** Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*